Amgen Inc.

Xian Yun Jiao

Frank Kayser

David John Kopecky

Derek Evan Piper

Sharon McKendry

Andrew K Shiau

Jonathan B Houze

Sean P Brown

Mario G Cardozo

Todd J Kohn

Marc Vimolratana

Julio Cesar Medina

Liusheng Zhu

Ming Yu

Zice Fu

Xiaolin Hao

Paul John Dransfield

Vatee Pattaropong

Yingcai Wang

Michael R Degraffenreid

Jiasheng Fu

Craig E Masse

Xiaohui Du

Wang Shen

Juan Carlos Jaen

Ryan D White

Xiaotian Zhu

Jian Luo

Xuelei Yan

Timothy David Cushing

Dustin L McMinn

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Jiwen Liu

Marc Labelle

Xianghong Wang

Youngsook Shin

Alan C Cheng

Jason A Duquette

Christopher Neil Farthing

Ana Zurisadai Gonzalez Buenrostro

Kexue Li

Zhihong Li

Gayathri Swaminath

Erin F DiMauro

An-Rong Li

John Laird Buchanan

Mike Elias Lizarzaburu

Jie Zhang

Yunxiao Li

Michael J Schmitt

YuMei Xiong

Sarah Elizabeth Lively

Manuel Zancanella

Joshua Taygerly

Yongli Su

Michael W Gribble, Jr

Jiang Zhu

SuJen Lai

Marie-Louise Smith

Margrit Schwarz

Yong-Jae Kim

William H Buckner

Andrew Smith

Jeffrey D Reagan

Simon A Burkitt

Qiong Cao

David Karl Bedke

Sven P Rasmussen

Daniel Lin

Li Yang

Susan A Tomlinson

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Substituted biphenyl GPR40 modulators

The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.

Antiinflammation agents

Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.

Heterocyclic arylsulfonamidobenzylic compounds

Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.

Arylsulfonamidobenzylic compounds

Growing community of inventors

San Mateo, CA, United States of America

Xian Yun Jiao